Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
5
Neutral
5
Bullish
4
Bearish
25
Neutral
5
Bullish
16
Bearish
20
Neutral
0
Bullish
12
Discovery themes featuring this stock
Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets.
The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up.
GTBL has completed significant capex: a new fermentation facility and a commercial API unit (operations from 6 May 2025), and its balance sheet shows PPE rising sharply and non‑current borrowings increasing, underlining an active investment phase to expand capacity and product mix.
Management disclosed R&D spend of about 3% of revenue for the nine months, ongoing validation batches for API blocks, and is establishing a new R&D center; the company targets forward integration and export expansion while also commissioning an 18.5 MW captive wind‑solar hybrid plant to reduce power costs and carbon footprint.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,928 Cr
High Risk
84.2
36.7
-19.3
13.7
479.45
225.75
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1258.40 | 4,358 Cr | — | 6.28 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
360.50 | 3,928 Cr | 84.23 | 13.65 | 0.19 | 16.22 | 14.47 | 9.27 | ||
539.90 | 3,797 Cr | 46.37 | 1.40 | 0.00 | 2.88 | 3.79 | 6.77 | ||
377.85 | 3,793 Cr | 59.10 | 5.70 | 0.03 | 9.66 | 11.45 | 4.78 | ||
405.05 | 3,693 Cr | 18.94 | 2.38 | 0.49 | 12.58 | 11.51 | 6.92 | ||
386.60 | 3,566 Cr | 34.97 | 4.54 | 0.11 | 12.98 | 12.14 | 6.46 | ||
| Median: 7 Co. | — | 405.05 | 3,797 Cr | 43.98 | 4.97 | 0.08 | 11.39 | 11.51 | 6.77 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Gujarat Themis Biosyn Ltd (GUJTHEM) is currently trading at 360.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets. The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up. GTBL has completed significant capex: a new fermentation facility and a commercial API unit (operations from 6 May 2025), and its balance sheet shows PPE rising sharply and non‑current borrowings increasing, underlining an active investment phase to expand capacity and product mix. Management disclosed R&D spend of about 3% of revenue for the nine months, ongoing validation batches for API blocks, and is establishing a new R&D center; the company targets forward integration and export expansion while also commissioning an 18.5 MW captive wind‑solar hybrid plant to reduce power costs and carbon footprint.
Over the past 52 weeks, Gujarat Themis Biosyn Ltd has traded between a low of ₹225.75 and a high of ₹479.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gujarat Themis Biosyn Ltd has a market capitalization of approximately 3,928.20. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gujarat Themis Biosyn Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 84.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,928.20 Cr, Gujarat Themis Biosyn Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gujarat Themis Biosyn Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gujarat Themis Biosyn Ltd is 84.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
They approved two special resolutions to increase borrowing powers (including creating charges on assets) and to authorise loans, guarantees and investments under Section 186 of the Companies Act, 2013.
The board approved raising up to ₹1,000 crore through a Qualified Institutions Placement (QIP) and a preferential issue of equity shares to non-promoters, subject to approvals.
It has approved raising up to ₹1,000 crore via a Qualified Institutions Placement (QIP) under SEBI ICDR Regulations, with additional funds potentially via a preferential issue to non-promoters.
It reported a net profit (PAT) of ₹46.68 crore for the year ended March 31, 2026.
Regulatory/Compliance Filing
Gujarat Themis Biosyn Ltd published a Postal Ballot notice in English & Gujarati newspapers on 24-07-2026 seeking shareholder approval for QIP (equity), amendment to AoA and private placement of NCDs/debt; e-voting 24-07-2026 to 22-08-2026.
AGM/EGM Notice
Gujarat Themis Biosyn published a Postal Ballot notice dated 24-07-2026 seeking shareholder approval for QIP (equity), amendment to AOA and private placement of NCDs/debt; e-voting 24-07-2026 to 22-08-2026.
Preferential Allotment/QIP
Gujarat Themis Biosyn Ltd: Notice of Postal Ballot dated 22-07-2026 seeking shareholder approval to raise funds via Qualified Institutions Placement (QIP). Remote e-voting 24-07-2026 to 22-08-2026; result by 25-08-2026.
Regulatory/Compliance Filing
Gujarat Themis Biosyn Ltd: Pharmaceutical Business Group (India) Ltd created a pledge (25,24,245 shares) and non-disposal undertaking (21,57,855) in favour of CTL Trusteeship, causing indirect encumbrance over 5,12,40,000 GTBL shares (47.02%).
Regulatory/Compliance Filing
Gujarat Themis Biosyn Ltd disclosure: Pharmaceutical Business Group (PBGIL) created a pledge (25,24,245) and non‑disposal undertaking (21,57,855), causing indirect encumbrance over 5,12,40,000 GTBL shares (47.02%).
Regulatory/Compliance Filing
Gujarat Themis Biosyn Ltd: PBGIL created a pledge of 25,24,245 shares (51%) and a non‑disposal undertaking over 21,57,855 shares (47.98%) in favour of CTL Trusteeship, causing indirect encumbrance on 5,12,40,000 GTBL shares (47.02%).
